They are gathering and assembling the data, studying why Imetelstat works in some cases, trying to understand the mechanism of action, preparing a publication draft for ASH, putting educational materials together for enhancing the academic understanding of imetelstat's properties, thinking about other trials where Imetelstat might have benefits, working on dosing and toxicity minimization, following up patient efficacy results and durability factors, communicating with the FDA and GERN, possibly about BTD status for imetelstat, and trying to get Imetelstat into further clinical trials for patients that can benefit, as well as trying to find a fit for GERN in the partnership arena.
MC has wide contacts among Big Pharma and GERN is looking for a big pharma partner to help with the Imetelstat program. Assuming that the MC thinks Imetelstat is a breakthrough drug, wouldn't you expect that they would be assisting GERN in all ways possible, including supplying data to help with the partnership discussions? Or is this still yet to come after the ASH data abstracts are published in November?
Tefferi quotes: “Imetelstat is capable of producing complete remission in some patients with myelofibrosis, suggesting disease-modifying activity,” said Ayalew Tefferi, MD, a hematologist at the Mayo Clinic in Rochester, Minnesota. “Imetelstat reverses bone marrow fibrosis and induces morphologic and molecular remissions in some patients with myelofibrosis. Imetelstat activity in myelofibrosis might be affected by the presence or absence of specific mutations,” he added. “A possible correlation between complete response and spliceosome mutations suggests a broader therapeutic application for the drug.”
Well, unlike high secrecy projects whereby Pharmas are testing and not wanting competition to know results, with the MC you have just the opposite. Rather refreshing, too. But, you have got to know that when their researchers get excited about results and potential applications that they are certainly going to get on the horn and spread the word to others.